{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:47:27Z","timestamp":1778500047266,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10620-019-05982-z","type":"journal-article","created":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T08:02:37Z","timestamp":1575705757000},"page":"2046-2053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center"],"prefix":"10.1007","volume":"65","author":[{"given":"Jason","family":"Reinglas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorant","family":"Gonczi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Verdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-6488","authenticated-orcid":false,"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,7]]},"reference":[{"key":"5982_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/jech.55.10.716","volume":"55","author":"LM Kurina","year":"2001","unstructured":"Kurina LM. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001;55:716\u2013720.","journal-title":"J Epidemiol Community Health"},{"key":"5982_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135\u2013149.","journal-title":"J Crohns Colitis"},{"key":"5982_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769\u2013784.","journal-title":"J Crohns Colitis"},{"key":"5982_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/apt.13445","volume":"43","author":"NS Ding","year":"2016","unstructured":"Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease\u2014algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"5982_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejim.2012.12.015","volume":"24","author":"E Sinagra","year":"2013","unstructured":"Sinagra E, Perricone G, Romano C, et al. Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. Eur J Int Med. 2013;24:385\u2013392.","journal-title":"Eur J Int Med"},{"key":"5982_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5\u00a0years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107:1409\u20131422.","journal-title":"Am J Gastroenterol"},{"key":"5982_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u2013721.","journal-title":"N Engl J Med"},{"key":"5982_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"5982_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/ajg.2016.236","volume":"111","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US Victory Consortium. Am J Gastroenterol. 2016;111:1147\u20131155.","journal-title":"Am J Gastroenterol"},{"key":"5982_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","volume":"113","author":"N Narula","year":"2018","unstructured":"Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the Victory Consortium. Am J Gastroenterol. 2018;113:1345\u20131354.","journal-title":"Am J Gastroenterol"},{"key":"5982_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116\u20131122.","journal-title":"Am J Gastroenterol"},{"key":"5982_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/MEG.0000000000000643","volume":"28","author":"H Thiebault","year":"2016","unstructured":"Thiebault H, Boyard-Lasselin P, Guignant C, et al. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. Eur J Gastroenterol Hepatol. 2016;28:876\u2013881.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5982_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","volume":"76","author":"G Varkas","year":"2017","unstructured":"Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017;76:878\u2013881.","journal-title":"Ann Rheum Dis"},{"key":"5982_CR14","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1093\/ibd\/izy127","volume":"24","author":"T Cai","year":"2018","unstructured":"Cai T, Lin T-C, Bond A, et al. The association between arthralgia and vedolizumab using natural language processing. Inflamm Bowel Dis. 2018;24:2242\u20132246.","journal-title":"Inflamm Bowel Dis"},{"key":"5982_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","volume":"13","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Sandborn WJ, Colombel J-F, et al. Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. J Crohns Colitis. 2019;13:50\u201357.","journal-title":"J Crohns Colitis"},{"key":"5982_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/apt.14419","volume":"47","author":"S Tadbiri","year":"2018","unstructured":"Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485\u2013493.","journal-title":"Aliment Pharmacol Ther"},{"key":"5982_CR17","first-page":"1932","volume":"25","author":"D Elewaut","year":"1998","unstructured":"Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol. 1998;25:1932\u20131937.","journal-title":"J Rheumatol"},{"key":"5982_CR18","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660\u20131666.","journal-title":"Inflamm Bowel Dis"},{"key":"5982_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","volume":"8","author":"S Vermeire","year":"2010","unstructured":"Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn\u2019s disease activity and Harvey\u2013Bradshaw indices in assessing Crohn\u2019s disease severity. Clin Gastroenterol Hepatol. 2010;8:357\u2013363.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5982_CR20","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2013.08.010","volume":"145","author":"M Ferrante","year":"2013","unstructured":"Ferrante M, Colombel J, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn\u2019s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145:978\u2013986.","journal-title":"Gastroenterology"},{"key":"5982_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","volume":"12","author":"T Engel","year":"2018","unstructured":"Engel T, Ungar B, Yung DE, et al. Vedolizumab in IBD-lessons from real-world experience; A systematic review and pooled analysis. J Crohns Colitis. 2018;12:245\u2013257.","journal-title":"J Crohns Colitis"},{"key":"5982_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","volume":"14","author":"A Amiot","year":"2016","unstructured":"Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:1593\u20131601.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5982_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.14167","volume":"46","author":"A Amiot","year":"2017","unstructured":"Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310\u2013321.","journal-title":"Aliment Pharmacol Ther"},{"key":"5982_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/apt.14919","volume":"48","author":"PG Kotze","year":"2018","unstructured":"Kotze PG, Ma C, Almutairdi A, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:626\u2013637.","journal-title":"Aliment Pharmacol Ther"},{"key":"5982_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","volume":"52","author":"C Eriksson","year":"2017","unstructured":"Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722\u2013729.","journal-title":"Scand J Gastroenterol"},{"key":"5982_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","volume":"11","author":"M Rosario","year":"2017","unstructured":"Rosario M, French JL, Dirks NL, et al. Exposure\u2013efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease. J Crohns Colitis. 2017;11:921\u2013929.","journal-title":"J Crohns Colitis"},{"key":"5982_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","volume":"17","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lasch K, Lissoos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:130\u2013138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5982_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","volume":"17","author":"L Peyrin-Biroulet","year":"2019","unstructured":"Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:838\u2013846.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5982_CR29","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","volume":"15","author":"N Williet","year":"2017","unstructured":"Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2017;15:1750\u20131757.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5982_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/apt.13813","volume":"44","author":"A Stallmach","year":"2016","unstructured":"Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1\u00a0year in patients with active inflammatory bowel disease\u2014a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199\u20131212.","journal-title":"Aliment Pharmacol Ther"},{"key":"5982_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.13594","volume":"43","author":"DC Baumgart","year":"2016","unstructured":"Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2014a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090\u20131102.","journal-title":"Aliment Pharmacol Ther"},{"key":"5982_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.dld.2018.07.040","volume":"51","author":"U Kopylov","year":"2019","unstructured":"Kopylov U, Avni-Biron I, Ron Y, et al. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease\u2014the Israeli real world experience. Dig Liver Dis. 2019;51:68\u201374.","journal-title":"Dig Liver Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05982-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05982-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05982-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:30:03Z","timestamp":1607214603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05982-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5982"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05982-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,7]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"JR, LG, and CV declare no conflict of interest. GW has been a speaker and\/or advisory board member for AbbVie, Janssen, Pfizer, Shire, and Takeda. ES has received unrestricted research grants from AbbVie and Janssen. AB has been a member of Advisory Boards\u2014Abbvie, Pfizer, Takeda, Janssen, Merck; Speaker\u2019s bureau\u2014Abbvie, Janssen, Takeda, Pfizer. TB has been a peaker or advisory board member for Takeda, Janssen, Abbvie, Merck, Pfizer, Pendopharm, Ferring, Shire. WA has been a speaker for Janssen, Prometheus, Dynacare, Takeda, AbbVie Theradiag. PLL has been a speaker and\/or advisory board member for AbbVie, Falk Pharma GmbH, Ferring, Genetech, Janssen, Kyowa Hakko Kirin Pharma, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer, Roche, Shire, and Takeda and has received unrestricted research grants from AbbVie, MSD, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}